Cyt-1010 is under clinical development by Cytogel Pharma and currently in Phase I for Post-Operative Pain. According to GlobalData, Phase I drugs for Post-Operative Pain have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cyt-1010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cyt-1010 overview
Cyt-1010 is under development for the treatment of post-operative pain, acute or chronic pain. Cyt-1010 is a proprietary compound and a chemically stabilized analogue of endomorphin 1, a naturally occurring pain modulator. It is administered through oral and intravenous route. It acts through Mu opioid receptors. The drug candidate is based on receptor targeting technology.
It was also under development for the treatment of acute and chronic pain conditions, including neuropathic pain.
Cytogel Pharma overview
Cytogel Pharma is a biopharmaceutical development company. It provides platform technologies and product candidates. The company offers novel analgesic product candidates and polymer and hydrogel drug delivery platform technologies. Its analgesic product candidates offer the control of various pain models. Cytogel Pharma provides pain relief and polymer systems used for making biological drugs. The company’s drug delivery technologies are used in various applications in human pharmaceuticals, medical devices and animal health pharmaceuticals. The company licenses its products to other larger companies for the full scientific and clinical development and subsequent commercialization. It caters pain management and drug dilevery sectors. Cytogel Pharma is headquartered in Darien, Connecticut, the US.
For a complete picture of Cyt-1010’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
